Quarterly ResultApr 30, 2026, 04:09 PM
CERS Q1 Total Revenue $59.9M, up 23%; Raises FY26 Guidance
AI Summary
Cerus Corporation announced strong first-quarter 2026 financial results, with total revenue increasing 23% to $59.9 million and product revenue up 24% to $53.7 million, driven by demand for INTERCEPT Fibrinogen Complex. The company significantly reduced its net loss to $1.6 million and reported positive non-GAAP adjusted EBITDA of $4.0 million. Consequently, Cerus raised its full-year 2026 product revenue guidance to $227 million - $231 million, reflecting 10% to 12% year-over-year growth. Additionally, Vivek Jayaraman will be appointed President and CEO, effective July 1, 2026.
Key Highlights
- Vivek Jayaraman to be appointed President & CEO, effective July 1, 2026.
- Q1 2026 Total Revenue $59.9M, up 23% from $48.9M in prior year.
- Q1 2026 Product Revenue $53.7M, up 24% from $43.2M in prior year.
- Raised FY26 Product Revenue Guidance to $227M-$231M, reflecting 10-12% YoY growth.
- Q1 2026 Net Loss $1.6M ($0.01/share), significantly down from $7.7M ($0.04/share) YoY.
- Q1 2026 Non-GAAP Adjusted EBITDA $4.0M, up from $0.2M in prior year.
- INTERCEPT Fibrinogen Complex (IFC) demand volumes increased approximately 120% YoY.
- Signed new four-year supply agreement with Établissement Français du Sang (EFS).